NCT05564611View on ClinicalTrials.gov

PK, PD, Safety & Immunogenicity of ADL-018 Lyo in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

November 4, 2022

Primary Completion Date

July 30, 2023

Study Completion Date

August 15, 2023

Conditions
Healthy
Interventions
DRUG

Omalizumab 150mg

A single dose of 150 mg lyophilized vial will be administered in the upper arm as the site of injection

Trial Locations (1)

384435

Registered BE centre, Mahesāna

Sponsors
All Listed Sponsors
lead

Kashiv BioSciences, LLC

INDUSTRY

NCT05564611 - PK, PD, Safety & Immunogenicity of ADL-018 Lyo in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter